In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Debiopharm gets ADC candidate from ImmunoGen

Executive Summary

ImmunoGen Inc. granted Debiopharm International SA all rights to its anti-CD37 antibody-drug conjugate IMGN529 (naratuximab emtansine) for B-cell malignancies. Debiopharm, which gains its first ADC project through the collaboration, will develop the candidate as DEBIO1562.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies